Mycenax Biotech Inc.


Please enter the company code as 4726 Go to Link

Pearl Fong, Associate VP, to give presentation in 9th Annual Biosimilars Asia.

15 – 17 May 2018, Pearl Fong, Mycenax Biotech Inc. vice present was invited as the speaker to share the experience and strategy for the development of biosimilars in the 9th Annual Biosimilars Asia.
The speech topic is “Global Development Strategy on Biosimilars: How to Win in the International Space.” Pearl used LusiNEX, which is a tocilizumab biosimilar as an example, to share the global development strategy established in accordance with the regulatory requirement, marketing performance, and partnering environment. Pearl also pointed out that Strategy Implementation is always driven by the Market size. Since the growth rate of biosimilar market in China is predicted to be the highest one among the world, it is expected, as already happened, the competition of biosimilar development in China is fierce.    
LusiNEX, is a biosimilar acting as interleukin-6 receptor (IL-6R) antagonist. By binding IL-6R, it blocks the inflammatory responses and alleviates joint erosion. LusiNEX is developed for the treatment of immunology and musculoskeletal disorders, including Rheumatoid arthritis (RA), polyarticular idiopathic juvenile arthritis (PJIA) and systemic juvenile idiopathic arthritis (SJIA).
Due to the growing aging population and advanced diagnosed technics, nearly 4.5 million adults are diagnosed with RA each year in global. Furthermore, one out of every 6 people in Asia suffers from RA, and this trend is expected to grow.  
However, the high cost of biologics limits the access of treatment and causes economic burdens among health authorities. As a CMC-based biotech dedicated to processing development of biologics, Mycenax reinforces its commitment to developing affordable, high-quality products to RA patients.
At IBC Asia’s 9th Annual Biosimilars Asia, top industry players come together to explore tactics for overcoming hurdles unique to biosimilars in China, and globally. A focus on partnerships and commercial opportunities will be complemented by insights on disruptive technologies in manufacturing, commercialization, risk management, and pharma co-vigilance.